A Randomized Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botulinum Toxin (Botox®) Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

Trial Profile

A Randomized Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botulinum Toxin (Botox®) Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INTIMO2
  • Sponsors UroGen Pharma
  • Most Recent Events

    • 15 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
    • 15 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 15 Jun 2017 Planned initiation date changed from 1 May 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top